Autoimmunity markers in subjects with diabetes
Journal Title: Journal of Pre-Clinical and Clinical Research - Year 2016, Vol 10, Issue 1
Abstract
[b]Introduction.[/b] Diabetes is a growing social and epidemiological problem. Accordingly, the incidence of complications associated with diabetes can cause a persistent high percentage of diseases of the cardiovascular system, kidney and nervous systems, and impaired vision. [b]Objective.[/b] The aim of the study was to evaluate the incidence of immunological markers in patients with type 1 diabetes and those with type 2 diabetes: the anti-GAD, ANA, AMA, ASMA, APCA and LKM, compared to healthy people. Another objective of the study was to evaluate the correlation between their presence and the degree of metabolic control in both groups. [b]Materials and methods[/b]. The study comprised 100 subjects aged 25–75 years with a body mass index (BMI) between 20–30 kg / m2, hospitalized in the Department of Internal Diseases, Diabetology and Endocrinology, at the Medical University of Warsaw, with previously diagnosed diabetes who were assigned to one of 2 groups (50 subjects with type 1 diabetes and 50 subjects with type 2 diabetes). The control group consisted of 21 healthy individuals without the diagnosis of diabetes and a prediabetic state. All the study participants had the examined antibodies determined along with the panel of biochemical tests and neurological examination for diabetic neuropathy and fundus examination. [b]Results. [/b]Anti-GAD antibodies were present in both groups of patients. Their presence was found in 30% of people with type 1 diabetes and in 16% of people with diabetes type 2. The presence of ANA antibodies was found in 24% of people with type 1 diabetes and 22% of people with type 2 diabetes. There was no correlation between the presence of ANA antibodies ANA and duration of diabetes. In the group of patients with type 1 diabetes, there was a correlation between the presence of ANA and the incidence of diabetic polyneuropathy. ASMA and APCA antibodies occurred with equal frequency in both studied groups (4% vs. 10%). There were no antibodies of AMA or anti-LKM in any of the patients. [b]Conclusions[/b]. Marking of ANA antibodies in patients with type 1 diabetes may be a marker used to isolate a group of patients at risk of developing diabetic neuropathy. The presence of anti-GAD in type 2 diabetes may be a LADA marker which specifically marks the group of patients with type 2 diabetes, in whom there is a faster metabolic death of beta cells. The current classification of diabetes is vague, and in the near future it should be modified based on specific patient characteristics, phenotypic appearance, as well as the results of additional tests. Determination of antibodies AMA, ASMA, APCA and anti-LKM does not seem to be significant in the diagnosis of diabetes and its chronic complications.
Authors and Affiliations
Joanna Litwińczuk-Hajduk, Małgorzata Bernat-Karpińska, Marek Kowrach, Paweł Piątkiewicz
Keywords
Related Articles
- EP ID EP79295
- DOI 10.5604/18982395.1208185
- Views 62
- Downloads 0
No effect of 7-nitroindazole on the anticonvulsant action of vigabatrin and oxcarbazepine in pentylenetetrazole-induced seizures in mice
The aim of this study was to determine the effect of 7-nitroindazole (7-NI – a preferential neuronal nitric oxide synthase inhibitor) on the protective action of oxcarbazepine (OXC) and vigabatrin (VGB) – two newer anti...
Effect of fribrinigen degradation products on various stages of the fibrinolytic process
Over-activation of the fibrinolytic system may result in proteolytic destruction of fibrinogen. However, the effect of the degradation products formed during fibrinogenolysis on fibrinolytic process and plasminogen/plasm...
Metallothioneins and its role in metal regulation, binding of reactive oxygen species, apoptosis and cell differentiation
Metallothioneins (MT) are the widespread proteins in animal world. These proteins are characterized by the low invariability of their structure. The number of aminoacids is fixed in every animal group, that is 60 (or 61...
Combination therapy of basal-cell carcinoma in 31-year-old patient with nevoid basal cell carcinoma syndrome – Case study
Nevoid basal cell carcinoma syndrome (NBCCS) is a rare genetic disease that is manifested in a number of disorders concerning the skin, skeleton, cardiovascular and nervous systems. Various defects which can be observed...
Life-threatening conditions in psychiatry – neuroleptic malignant syndrome (NMS)
The introduction of neuroleptics in the 1950’s was a turning point in psychiatric treatment. The new drugs brought hope to millions of patients and their doctors. However, there were also some side-effects, one of which...